Authors :
Presenting Author: Osama Muthaffar, MD, SBPN, ABCN, CSCN – King Abdulaziz University
Anas Alyazidi, MD – Department of Pediatrics, Faculty of Medicince, King Abdulaziz University, Jeddah, Saudi Arabia; Layan Baaishrah, MD – Department of Pediatrics, Faculty of Medicince, King Abdulaziz University, Jeddah, Saudi Arabia; Hussain Alkhalifah, MD – Department of Pediatrics, Faculty of Medicince, King Abdulaziz University, Jeddah, Saudi Arabia; Maya khider, MD – Department of Pediatrics, Faculty of Medicince, King Abdulaziz University, Jeddah, Saudi Arabia; Rafah Hariri, MD – Department of Pediatrics, Faculty of Medicince, King Abdulaziz University, Jeddah, Saudi Arabia; Sereen Alahmadi, MD – Department of Pediatrics, Faculty of Medicince, King Abdulaziz University, Jeddah, Saudi Arabia
Rationale:
Dravet Syndrome is a form of genetic epilepsy with early-onset, intractable epilepsy and neurodevelopmental delay. In children, DS can lead to refractory seizures that are resistant to standard therapy. Recently, perampanel was approved as an antieseizure drug for patients as young as four years old. Few studies discussed the efficacy of perampanel in children with Dravet syndrome.
Methods:
The medical records at King Abdulaziz University Hospital were retrospectively reviewed. Patients with DS and using perampanel were included in the study. The collected data included their demographic characteristics, seizure pattern, perampanel dosage, laboratory and imaging findings.
Results:
The study included 18 pediatric patients with a clinical diagnosis of DS. Mean age of perampanel initiation was 7.67 years ± 3.8. Majority of patients had two types of seizures (61.1%) followed by three types (22.2%). Generalized tonic-clonic was the most frequently reported type of seizure. The mean efficacy of perampanel was 29.17% ± 29.3, with one patient with 100% efficacy to perampanel. Perampanel duration in weeks was 37.22 week ± 48.35. Patients aged eight years and younger presented with higher efficacy (p-value = 0.037) and the number of side effect was positively correlated with the efficacy.
Conclusions:
This study presented supporting evidence of the promising therapeutic effect for perampanel among patients with Dravet syndrome. Perampanel can be considered as one of the treatment options for patients with Dravet syndrome.
Funding: None